NEW YORK (Reuters Health) Jun 24 –
Results of a double-blind tolerability study suggest that 900 mg rifapentine–300 mg more than the standard dose–plus isoniazid once-weekly is safe and well tolerated in the continuation phase of tuberculosis (TB) treatment.
In the June 1st issue of the American Journal of Respiratory and Critical Care Medicine, investigators note that rifapentine offers a “major public health advantage” over other anti-TB agents because it need only be taken once a week.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!